Please login to the form below
azacitidine
This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.
BMS’s oral AML therapy Onureg receives EU approval
Onureg (azacitidine tablets) has been cleared for the treatment of AML patients who have achieved complete remission (CR) or CR with incomplete blood count recovery (CRi), following first-line chemotherapy with
Latest news
-
Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021
and azacitidine had improved survival outcomes compared with those who were MRD-positive following treatment. ... In May, the European Commission (EC) approved Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed
-
J&J exits $1.6bn blood cancer drug licensing deal with argenx
The ongoing, early-stage trial is evaluating cusatuzumab in combination with AbbVie/Roche’s Venclexta (venetoclax) and chemotherapy Vidaza (azacitidine) in newly-diagnosed, elderly patients with AML.
-
EC approves Venclyxto-based combinations for newly diagnosed AML
The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who can’t ... In the US, Venclyxto is approved as
-
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
Researchers found that Venclyxto (venetoclax) – known as Venclexta in the US – in combination with azacitidine extended overall survival (OS) compared to the azacitidine plus placebo arm. ... The safety profile of the treatment was found to be
-
Givlaari, Rybelsus lead crowded CHMP recommendations
a host of other indications, as well as azacitidine betapharm (azacytidine) and azacitidine Mylan (azacitidine) for the treatment of a number of blood cancers.
Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021
J&J exits $1.6bn blood cancer drug licensing deal with argenx
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
Givlaari, Rybelsus lead crowded CHMP recommendations
More from news
Approximately 2 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient
Drug launches to watch in 2019
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
